Overview
Hernan Carranza practices in Bogota, Colombia. Mr. Carranza is rated as an Experienced expert by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Lung Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC).
His clinical research consists of co-authoring 33 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- EGFR Positive Lung CancerMr. Carranza isDistinguished. Learn about EGFR Positive Lung Cancer.
- Lung CancerMr. Carranza isDistinguished. Learn about Lung Cancer.
- Advanced
- Lung AdenocarcinomaMr. Carranza isAdvanced. Learn about Lung Adenocarcinoma.
- Non-Small Cell Lung Cancer (NSCLC)Mr. Carranza isAdvanced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Small Cell Lung Cancer (SCLC)Mr. Carranza isAdvanced. Learn about Small Cell Lung Cancer (SCLC).
- Experienced
- AstrocytomaMr. Carranza isExperienced. Learn about Astrocytoma.
- Brain TumorMr. Carranza isExperienced. Learn about Brain Tumor.
- Cervical CancerMr. Carranza isExperienced. Learn about Cervical Cancer.
- GlioblastomaMr. Carranza isExperienced. Learn about Glioblastoma.
- GliomaMr. Carranza isExperienced. Learn about Glioma.
- Gliomatosis CerebriMr. Carranza isExperienced. Learn about Gliomatosis Cerebri.